#United States #New York #Class Action #ESSA Pharma #Bronstein Gewirtz

ESSA Pharma Inc. Class Action Lawsuit Overview

In a recent development concerning ESSA Pharma Inc. (NASDAQ: EPIX), Bronstein, Gewirtz & Grossman, LLC, a recognized national law firm, has initiated a class action lawsuit targeting the company and certain executives. This lawsuit stems from numerous alleged violations of federal securities laws that could have impacted investors significantly.

Class Definition and Timeline

The class action encompasses all individuals or entities that purchased or acquired ESSA's securities between December 12, 2023, and October 31, 2024. This timeframe, known as the “Class Period,” is critical for those who wish to participate in the lawsuit. The law firm emphasizes that interested investors should act swiftly to ensure their rights are protected. The firm invites affected parties to visit their website at bgandg.com/EPIX to learn more about joining the case.

Allegations Against ESSA Pharma

The crux of the complaint alleges that during the Class Period, the defendants—including certain officers of ESSA Pharma—provided misleading and materially false statements concerning the company's operational health and future prospects. Key allegations include:
1. Ineffective Treatment: Claims were made suggesting that the drug masofaniten combined with enzalutamide demonstrated clear efficacy over enzalutamide alone. However, further analysis shows there are no substantial benefits to this combination for prostate cancer treatment.
2. Failure to Meet Study Goals: Certain clinical studies, including the M-E Combination Study, are reported to be unlikely to meet their initial objectives, undermining the perceived potential of masofaniten in clinical settings.
3. Overstated Clinical Prospects: The allegations extend to the overstatement of masofaniten's commercial viability and regulatory potential, which could mislead investors regarding the company's prospects.
4. Materially Misleading Public Statements: Overall, the defendants’ public representations during the Class Period are contended to be fundamentally deceptive, impacting the market's perception of the company's legitimacy.

Steps for Affected Investors

Investors who have experienced financial losses due to their association with ESSA Pharma are encouraged to reach out. The time is of the essence, as those wishing to be recognized as lead plaintiffs in this case have until March 25, 2025, to submit their request to the court. Importantly, involvement as a lead plaintiff is not a prerequisite for recovering any potential compensation.

No Financial Risk to Investors

Bronstein, Gewirtz & Grossman operates on a contingency fee basis. This means that they only collect fees if they win the case, significantly reducing the financial risk for the involved investors. Their established history of recovering hundreds of millions for clients facing similar circumstances reinforces their capability and reliability in handling such class action lawsuits.

Ongoing Updates and Support

Investors can stay updated on the case through the firm’s social media platforms, including LinkedIn, X (formerly Twitter), Facebook, and Instagram. For direct inquiries, parties may contact Peretz Bronstein, Esq., or Nathan Miller at 332-239-2660. The firm’s commitment to transparency and support for investors remains unwavering as they navigate this legal challenge.

In summary, the class action lawsuit against ESSA Pharma Inc. opens the door for affected investors to seek justice and financial recovery due to alleged misrepresentation by the company's leadership. With a firm like Bronstein, Gewirtz & Grossman advocating on their behalf, many may find renewed hope in these legal proceedings.